Insider · CIK 0001591109
Michael Mendelsohn
Files at FHTX (Foghorn Therapeutics Inc.). First filing -, latest -.
In brief
Michael Mendelsohn files SEC Form 4 as director at FHTX (Foghorn Therapeutics Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Michael Mendelsohn has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 24, 2026 | FHTX Foghorn Therapeutics Inc. | AGrant or award Stock Options (Right to buy)derivative | +28,000 | $4.08 | $114k | 28,000 | Jun 25, 2026 |
| Jun 17, 2025 | FHTX Foghorn Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +25,000 | $4.79 | $120k | 25,000 | Jun 17, 2025 |
Questions about Michael Mendelsohn
Answered from the filings on this page, as of the latest one.
Is Michael Mendelsohn buying or selling?
Michael Mendelsohn has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Michael Mendelsohn's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Michael Mendelsohn has 0.
Where does Michael Mendelsohn file Form 4?
Michael Mendelsohn has filed Form 4 at FHTX (Foghorn Therapeutics Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.